Simvastatin reduces melanoma progression in a murine model

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1763-1770

  Zanfardino, Mario ^a   Spampanato, Carmine ^b   De Cicco, Rosanna ^a   Buommino, Elisabetta ^b   De Filippis, Anna ^b   Baiano, Salvatore ^a   Barra, Adriano ^a   Morelli, Franco ^a  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Apoptosis; Melanoma progression; NonO; Simvastatin

Indexed keywords

SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NICK END LABELING; NONHUMAN; NONO GENE; PRIORITY JOURNAL; TUMOR VOLUME; WOUND HEALING;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SIMVASTATIN; SKIN NEOPLASMS; SURVIVAL; SURVIVAL RATE; WOUND HEALING;

EID: 84891957500     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2126     Document Type: Article

References (48)

1. Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F: Simvastatin inhibit cancer cell growth inducing apoptosis correlated to activation of Bax and downregulation of BCL2 gene expression. Int J Oncol 40: 935-941, 2012.
2. Gauthaman K, Fong CY and Bongso A: Statins, stem cells, and cancer. J Cell Biochem 106: 975-983, 2009.
3. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
4. Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
5. Lee MH, Yee Cho S and Han YM: Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cell 25: 1654-1663, 2007.
6. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003.
7. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005.
8. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA and Dimitroulakos J: Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11: 2398-2407, 2005.
9. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMBCoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002.
10. Wu J, Wong WW, Khosravi F, Minden MD and Penn LZ: Blocking the Raf-MEK-ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468, 2004.
11. Cafforio P, Dammacco F, Gernone A and Silvestris F: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891, 2005.
12. Mady EA: Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol 75: 323-328, 2000.
13. Nygren C, von Holst H, Mansson JE and Fredman P: Increased levels of cholesterol esters in glioma tissue and surrounding areas of human brain. Br J Neurosurg 11: 216-220, 1997.
14. Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F and Skoog L: Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2: 143-147, 1985.
15. Kokoglu E, Gorseval A, Sonmez H and Ozyurt E: Tissue lipid composition of human gliomas and meningiomas. Cancer Lett 65: 169-171, 1992.
16. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005.
17. Shannon J, Tewoderos S, Garzotto M, Beer TM, et al: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162: 318-325, 2005.
18. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, et al: The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control 22: 417-426, 2011.
19. Kim K: Statin and cancer risks: from tasseomancy of epidemiologic studies to meta-analyses. J Clin Oncol 24: 4796-4797, 2006.
20. Dale KM, Coleman CI, Henyan NN, Kluger J and White CM: Statins and cancer risk: a meta-analysis. JAMA 295: 74-80, 2006.
21. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, et al: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98: 69-72, 2006.
22. Chang CC, Ho SC, Chiu HF and Yang CY: Statins increase the risk of prostate cancer: A population-based case-control study. Prostate 71: 1818-1824, 2011.
23. Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, et al: Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 6: e28813, 2011.
24. Lee SK, Kim YC, Song SB, Young BS and Kim S: Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun 391: 1592-1597, 2010.
25. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, et al: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by down-regulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161: 17-26, 2002.
26. Herrero-Martin G and Lopez-Rivas A: Statins activate a mitochondrial-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by Erb B2 and dependent on the prenylation of proteins. FEBS Lett 582: 2589-2594, 2008.
27. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
28. Chipuk JE and Green DR: Dissecting p53-dependent apoptosis. Cell Death Differ 13: 994-1002, 2006.
29. nrb and the 14-3-3 protein HS1 as TNF-α-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol 38: 447-456, 2005.
30. nrb, a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and Drosophila NONA/BJ6. Nucleic Acids Res 21: 4085-4092, 2003.
31. Shav-Tal Y and Zipori D: PSF and p54(nrb)/NonO - multi-functional nuclear proteins. FEBS Lett 531: 109-114, 2002.
32. Zhang Z and Carmichael GG: The fate of dsRNA in the nucleus: a p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 106: 465-475, 2001.
33. nrb/NonO. Mol Cell Biol 17: 677-686, 1997.
34. nrb associates with the 50 splice site within large transcription/splicing complexes. EMBO J 23: 1782-1791, 2004.
35. Urban RJ, Bodenburg Y, Kurosky A, Wood TG and Gasic S: Polypyrimidine tract-binding protein-associated splicing factor is a negative regulator of transcriptional activity of the porcine p450scc insulin-like growth factor response element. Mol Endocrinol 14: 774-782, 2000.
36. Mathur M, Tucker PW and Samuels HH: PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Mol Cell Biol 21: 2298-2311, 2001.
37. Patton JG, Porro EB, Galceran J, Tempst P and Nadal-Ginard B: Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev 7: 393-406, 1993.
38. nrb bind a conserved stem in U5 snRNA. RNA 8: 1334-1347, 2002.
39. nrb/nonO bind to the RNA polymerase II CTD. RNA 8: 1102-1111, 2002.
40. Xing Y, Johnson CV, Dobner PR and Lawrence JB: Higher level organization of individual gene transcription and RNA splicing. Science 259: 1326-1330, 1993.
41. Yang YS, Hanke JH, Carayannopoulos L, et al: NonO, a non-POU-domain- containing, octamer-binding protein, is the mammalian homolog of Drosophila nonAdiss. Mol Cell Biol 13: 5593-5603, 1993.
42. Bosserhoff AK: Melanoma inhibitory activity (MIA) an important molecule in melanoma development and progression. Pigment Cell Res 18: 411-416, 2005.
43. Schmid R, Schiffner S, Opolka A, Grässel S, Schubert T, Moser M, Bosserhoff AK, et al: Enhanced cartilage regeneration in MIA/CD-RAP deficient mice. Cell Death Dis 11: e97, 2010.
44. nrb is a new regulator of progression of malignant melanoma. Carcinogenesis 32: 1176-1182, 2011.
45. 5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59: 5307-531, 1999.
46. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, et al: Breast cancer growth prevention by statins. Cancer Res 66: 8707-8714, 2006.
47. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, et al: Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67: 4524-4532, 2007.
48. 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 274: 12-418, 2009.